Ann: Race Appoints George Clinical for Phase 1 Trial of RC220, page-68

Firstly, great to see companies interacting with posters in this way on this forum, is a positive for building reputation and credibility, we don't see enough of this on HC.

Second, on the dose, out of curiosity, why start lower than Mason14 is predicting? You already have data in >140 patients for bisantrene at 320mg/m2 in the phase 3 breast cancer trial. Admittedly it's very old so practices change, single agent comparison and I assume a different formulation? The report I found states bisantrene was inferior to doxo wrt response rate (13% vs 28%) and survival was also marginally in favour of doxo. But bisantrene was less toxic. My point is RACE has a good body of safety data at dose >300mg/m2, but the efficacy didn't look great in that study vs doxo. (Cowan, J Nat Cancer Inst 1991)